An RNA aptamer-based biomarker platform demonstrates high soluble cd25 occupancy by il2 in the serum of follicular lymphoma patients

Suresh Veeramani, Sue E. Blackwell, William H. Thiel, Zhi Zhang Yang, Stephen Maxted Ansell, Paloma H. Giangrande, George J. Weiner

Research output: Contribution to journalArticle

Abstract

Ligand receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additional and valuable clinical and research tool for assessing whether receptors are occupied by a ligand. To address this need, a biomarker platform was developed to quantify the fraction of receptors occupied by a ligand using pairs of RNA aptamers, where one aptamer binds preferentially to the unoccupied receptor and the other to the ligand-receptor complex. Bound aptamer was quantified using RT-qPCR colorimetric probes specific for each aptamer. The binding ratio of aptamer correlated with the fraction of receptors occupied by a ligand. This assay, termed as LIRECAP (LIgand-REceptor Complex-binding APtamer) assay, was used to determine the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently. In contrast, the fraction of soluble CD25 occupied by IL2 was significantly higher in follicular lymphoma patient serum compared with diffuse large B-cell lymphoma patient serum. We conclude that this technology has the potential to serve as a highthroughput biomarker platform to quantify the fraction of receptors occupied by a ligand.

Original languageEnglish (US)
Pages (from-to)1511-1522
Number of pages12
JournalCancer Immunology Research
Volume7
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nucleotide Aptamers
Follicular Lymphoma
Biomarkers
Ligands
Serum
Interleukin-2
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Allergy and Immunology
Lymphoma
Technology

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

An RNA aptamer-based biomarker platform demonstrates high soluble cd25 occupancy by il2 in the serum of follicular lymphoma patients. / Veeramani, Suresh; Blackwell, Sue E.; Thiel, William H.; Yang, Zhi Zhang; Ansell, Stephen Maxted; Giangrande, Paloma H.; Weiner, George J.

In: Cancer Immunology Research, Vol. 7, No. 9, 01.01.2019, p. 1511-1522.

Research output: Contribution to journalArticle

Veeramani, Suresh ; Blackwell, Sue E. ; Thiel, William H. ; Yang, Zhi Zhang ; Ansell, Stephen Maxted ; Giangrande, Paloma H. ; Weiner, George J. / An RNA aptamer-based biomarker platform demonstrates high soluble cd25 occupancy by il2 in the serum of follicular lymphoma patients. In: Cancer Immunology Research. 2019 ; Vol. 7, No. 9. pp. 1511-1522.
@article{d218359ad9a3403cb89f4fe840f5fc6a,
title = "An RNA aptamer-based biomarker platform demonstrates high soluble cd25 occupancy by il2 in the serum of follicular lymphoma patients",
abstract = "Ligand receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additional and valuable clinical and research tool for assessing whether receptors are occupied by a ligand. To address this need, a biomarker platform was developed to quantify the fraction of receptors occupied by a ligand using pairs of RNA aptamers, where one aptamer binds preferentially to the unoccupied receptor and the other to the ligand-receptor complex. Bound aptamer was quantified using RT-qPCR colorimetric probes specific for each aptamer. The binding ratio of aptamer correlated with the fraction of receptors occupied by a ligand. This assay, termed as LIRECAP (LIgand-REceptor Complex-binding APtamer) assay, was used to determine the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently. In contrast, the fraction of soluble CD25 occupied by IL2 was significantly higher in follicular lymphoma patient serum compared with diffuse large B-cell lymphoma patient serum. We conclude that this technology has the potential to serve as a highthroughput biomarker platform to quantify the fraction of receptors occupied by a ligand.",
author = "Suresh Veeramani and Blackwell, {Sue E.} and Thiel, {William H.} and Yang, {Zhi Zhang} and Ansell, {Stephen Maxted} and Giangrande, {Paloma H.} and Weiner, {George J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/2326-6066.CIR-18-0821",
language = "English (US)",
volume = "7",
pages = "1511--1522",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - An RNA aptamer-based biomarker platform demonstrates high soluble cd25 occupancy by il2 in the serum of follicular lymphoma patients

AU - Veeramani, Suresh

AU - Blackwell, Sue E.

AU - Thiel, William H.

AU - Yang, Zhi Zhang

AU - Ansell, Stephen Maxted

AU - Giangrande, Paloma H.

AU - Weiner, George J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ligand receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additional and valuable clinical and research tool for assessing whether receptors are occupied by a ligand. To address this need, a biomarker platform was developed to quantify the fraction of receptors occupied by a ligand using pairs of RNA aptamers, where one aptamer binds preferentially to the unoccupied receptor and the other to the ligand-receptor complex. Bound aptamer was quantified using RT-qPCR colorimetric probes specific for each aptamer. The binding ratio of aptamer correlated with the fraction of receptors occupied by a ligand. This assay, termed as LIRECAP (LIgand-REceptor Complex-binding APtamer) assay, was used to determine the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently. In contrast, the fraction of soluble CD25 occupied by IL2 was significantly higher in follicular lymphoma patient serum compared with diffuse large B-cell lymphoma patient serum. We conclude that this technology has the potential to serve as a highthroughput biomarker platform to quantify the fraction of receptors occupied by a ligand.

AB - Ligand receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additional and valuable clinical and research tool for assessing whether receptors are occupied by a ligand. To address this need, a biomarker platform was developed to quantify the fraction of receptors occupied by a ligand using pairs of RNA aptamers, where one aptamer binds preferentially to the unoccupied receptor and the other to the ligand-receptor complex. Bound aptamer was quantified using RT-qPCR colorimetric probes specific for each aptamer. The binding ratio of aptamer correlated with the fraction of receptors occupied by a ligand. This assay, termed as LIRECAP (LIgand-REceptor Complex-binding APtamer) assay, was used to determine the fraction of soluble CD25 occupied by IL2 in the serum from subjects with B-cell lymphoma. No correlation was found between the type of lymphoma and total soluble CD25 or IL2 independently. In contrast, the fraction of soluble CD25 occupied by IL2 was significantly higher in follicular lymphoma patient serum compared with diffuse large B-cell lymphoma patient serum. We conclude that this technology has the potential to serve as a highthroughput biomarker platform to quantify the fraction of receptors occupied by a ligand.

UR - http://www.scopus.com/inward/record.url?scp=85071782331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071782331&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-18-0821

DO - 10.1158/2326-6066.CIR-18-0821

M3 - Article

C2 - 31383650

AN - SCOPUS:85071782331

VL - 7

SP - 1511

EP - 1522

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 9

ER -